Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegloticase in Tumor Lysis Syndrome
NCT04745910Phase 4Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2022
- Primary completion
- Apr 2026
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegloticase in tumor lysis syndrome (TLS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Response rate at 24 hours. Started Apr 2022; status: completed.
02
Drugs
pegloticase
03
Conditions
tumor lysis syndrome (TLS)
Beyond the preview
Go deeper on NCT04745910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04745910.